McKesson announced on August 25, 2026, that it will acquire Precision Medicine Group for approximately $2.25 billion to bolster its clinical research and oncology services. Precision Medicine Group will join McKesson's oncology and multispecialty unit, which saw revenue rise 33% to $14.2 billion in Q1 fiscal 2026. The deal aligns with McKesson's broader strategy to divest non-core assets, including selling a minority stake in its medical-surgical unit to Apollo Funds for $1.25 billion.
Precision Medicine Group acquisition
- ▪Bethesda, Maryland-based Precision Medicine Group will become part of McKesson's oncology and multispecialty unit after the acquisition deal closes
- ▪McKesson announced on August 25, 2026, that it will acquire privately held Precision Medicine Group in a deal valued at approximately $2.25 billion
McKesson portfolio restructuring strategy
- ▪McKesson is reshaping its portfolio by exiting non-core assets and streamlining operations while investing in oncology and specialty care to drive long-term growth
- ▪McKesson restructured its operations into four reporting segments in 2025
Clinical research services expansion
- ▪McKesson Chief Executive Officer Brian Tyler stated that the acquisition of Precision Medicine Group will enhance McKesson's clinical research, commercialization services, and clinical trial execution
- ▪Precision Medicine Group provides clinical research, laboratory testing, and commercialization services to help biotechnology and pharmaceutical companies develop and launch new medicines
Oncology division revenue growth
- ▪Revenue in McKesson's oncology and multispecialty division increased 33% to $14.2 billion in the first quarter of fiscal 2026
- ▪The revenue growth in McKesson's oncology and multispecialty division was driven by healthcare provider services, specialty distribution, and acquisitions of controlling stakes in Core Ventures and PRISM Vision Holdings
Medical-surgical business divestiture
- ▪McKesson announced in April 2026 that it would sell a minority stake in its medical-surgical solutions business to investment firm Apollo Funds for $1.25 billion
- ▪McKesson is pursuing an initial public offering for its medical-surgical solutions business following the sale of a minority stake to Apollo Funds
Story comments
Loading comments…